Dichlorphenamide is a carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. It is available as tablets for oral use. MedsAcross supplies Dichlorphenamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. KEVEYIS is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants
Source: US FDA prescribing information
Dichlorphenamide is a carbonic anhydrase inhibitor. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown.
Source: US FDA prescribing information
Initiate dosing at 50 mg by mouth once or twice daily. Titrate up or down dose based on individual response. The minimum recommended dosage is 50 mg daily, and the maximum recommended dosage is 200 mg daily. Evaluate response to KEVEYIS after 2 months of treatment
Source: US FDA prescribing information
KEVEYIS is contraindicated in the following circumstances: Hypersensitivity to dichlorphenamide or other sulfonamides Concomitant use of KEVEYIS and high dose aspirin Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy. Hepatic insufficiency. Severe pulmonary obstruction. Hypersensitivity to dichlorphenamide or other sulfonamides. Concomitant use with high dose aspirin
Source: US FDA prescribing information
Hypersensitivity and Other Life-Threatening Reactions: discontinue KEVEYIS at the first appearance of skin rash or any sign of immune-mediated or idiosyncratic adverse reaction. Hypokalemia: baseline and periodic measurements of serum potassium are recommended, if hypokalemia develops or persists, consider reducing the dose or discontinuing KEVEYIS and correcting potassium levels. Metabolic acidosis: baseline and periodic measurements of serum bicarbonate are recommended, if metabolic acidosis develops or persists, consider reducing the dose or discontinuing KEVEYIS. Falls: consider reducing the dose or discontinuing KEVEYIS in patients who experience falls
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in labeling: Hypersensitivity and Other Life-Threatening Reactions Hypokalemia Metabolic Acidosis Falls Most common adverse reactions (incidence at least 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state
Source: US FDA prescribing information
Aspirin: anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. The concomitant use of KEVEYIS and high-dose aspirin is contraindicated. KEVEYIS should be used with caution in patients receiving lower doses of aspirin
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Dichlorphenamide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dichlorphenamide 50 mg tabletOralGeneric name | — | US FDA | Available on request |
| Keveyis 50 mg tabletOral | Xeris Pharmaceuticals | US FDA | Available on request |
| Ormalvi 50 mg tabletOral | Cycle Pharmaceuticals | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 22 July 1958 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Dichlorphenamide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Dichlorphenamide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Dichlorphenamide, including Keveyis, Ormalvi.
Yes. The US FDA first approved Dichlorphenamide on 22 July 1958, according to Drugs@FDA.
No listed presentation of Dichlorphenamide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Dichlorphenamide is classified under ATC code S01EC02 (Dichlorphenamide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.